Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Verena Berger

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
BMC Proceedings|March 1, 2012
Cell line development using the SEFEX systemBenedikt Greulich, Verena Berger, Marika Poppe, et al.
Therapeutic Advances in Chronic Disease|January 22, 2024
The totality of evidence approach in the development of AVT02 (adalimumab), a biosimilar to HumiraJoseph E McClellan, Sesselja Ómarsdóttir, Nivedita Roy, et al.
Protein Engineering, Design & Selection : PEDS|September 6, 2013
An anti-TNFR1 scFv-HSA fusion protein as selective antagonist of TNF actionVerena Berger, Fabian Richter, Kirstin Zettlitz, et al.
BMC Proceedings|March 1, 2012
Process development of ATROSAB, an anti TNFR1 Monoclonal Antibody: in three steps from research to GMPKarlheinz Landauer, Cuneyt Unutmaz, Simon Egli, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
BMC Proceedings|March 1, 2012
Cell line development using the SEFEX systemBenedikt Greulich, Verena Berger, Marika Poppe, et al.
Therapeutic Advances in Chronic Disease|January 22, 2024
The totality of evidence approach in the development of AVT02 (adalimumab), a biosimilar to HumiraJoseph E McClellan, Sesselja Ómarsdóttir, Nivedita Roy, et al.
Protein Engineering, Design & Selection : PEDS|September 6, 2013
An anti-TNFR1 scFv-HSA fusion protein as selective antagonist of TNF actionVerena Berger, Fabian Richter, Kirstin Zettlitz, et al.
BMC Proceedings|March 1, 2012
Process development of ATROSAB, an anti TNFR1 Monoclonal Antibody: in three steps from research to GMPKarlheinz Landauer, Cuneyt Unutmaz, Simon Egli, et al.
Pageof 1